Liver cancer symptoms are notoriously quiet in the early stages, which is why the disease is so often found late — and why one specific group of people is offered a check-up every six months rather than waiting for warning signs. Most primary liver cancers grow inside a liver that has already been damaged by chronic hepatitis, alcohol, or metabolic disease, and a healthy liver has enough reserve to keep working normally while a small tumor develops. In this article you will learn which symptoms actually point to the liver, who qualifies for six-month surveillance and who does not, what an alpha-fetoprotein blood result can and cannot tell you, how doctors can sometimes diagnose liver cancer on imaging alone, and how treatment is chosen stage by stage.
What liver cancer is, and why the type matters
The word “liver cancer” covers three very different situations that readers frequently mix up. Getting the distinction right changes everything about testing, prognosis, and treatment.
Primary liver cancer
Primary liver cancer starts in the liver itself. About nine in ten cases are hepatocellular carcinoma, a tumor that grows from hepatocytes, the main working cells of the liver. Hepatocellular carcinoma is closely tied to long-term liver injury, and it usually appears in a liver that has already developed scarring. A much smaller share of primary tumors are cholangiocarcinoma, which starts in the bile ducts rather than the liver cells and behaves like a separate disease with its own tests and treatments.
Liver metastases
Liver metastases are deposits of a cancer that began somewhere else and traveled to the liver. They are far more common than primary liver tumors, and they are not treated as liver cancer at all — a bowel tumor that spreads to the liver is still bowel cancer under the microscope and still responds to bowel cancer drugs. Cancer teams see liver spread most often in people who have colorectal cancer, and they also see it frequently in people treated for pancreatic cancer. If a scan report mentions “liver lesions” in someone with a known cancer elsewhere, metastasis is usually the first explanation a doctor considers.
Liver cancer symptoms and what they actually mean
Early hepatocellular carcinoma typically produces no symptoms at all. When symptoms do appear, many of them come from the underlying liver disease rather than from the tumor, which is one reason they are easy to dismiss.
Signs that people notice first
- Discomfort or a dull ache in the upper right side of the abdomen, sometimes reaching the right shoulder blade
- A firm lump or fullness felt just below the ribs on the right
- Unexplained weight loss and a shrinking appetite
- Persistent tiredness that rest does not fix
- Nausea, or feeling full after only a few bites
Signs that point to liver function itself
- Yellowing of the skin and the whites of the eyes, known as jaundice
- Dark urine, or pale and chalky stools
- Abdominal swelling from fluid build-up, called ascites
- Bruising or bleeding more easily than usual
- Itchy skin without a rash
None of these findings is specific to cancer. Gallstones, viral hepatitis, medication reactions and alcohol-related liver injury produce the same picture, and most people with these symptoms do not have a liver tumor. The point is not to self-diagnose but to get the liver looked at properly.
When to see a doctor
Book an appointment without waiting if you notice yellowing of the eyes or skin, a new lump under the right ribs, abdominal swelling that develops over days or weeks, or weight loss you cannot explain. Seek care the same day if jaundice comes with fever and severe abdominal pain, if you vomit blood or pass black tarry stools, or if you become confused or unusually drowsy — these are signs of decompensating liver disease that need urgent assessment regardless of the cause.
What causes liver cancer and who is at higher risk
Nearly every risk factor for hepatocellular carcinoma works the same way: it injures the liver repeatedly over years, the liver scars, and the constant repair cycle raises the chance that a cell turns cancerous.
The main drivers
Long-term viral hepatitis remains the largest global cause. Many people in this group already manage chronic hepatitis B infection, which is unusual because it can lead to liver cancer even without full cirrhosis. Liver teams also follow chronic hepatitis C infection, which today is curable in most people with a short course of antiviral tablets. Heavy, sustained alcohol use is a second major driver. The third — and the fastest growing cause in the United States — is metabolic dysfunction-associated steatotic liver disease, or MASLD, the newer name for fatty liver linked to excess weight, type 2 diabetes, high blood pressure, and abnormal cholesterol.
Most cases develop in a liver that already shows the advanced scarring known as cirrhosis. Additional contributors include inherited iron overload (hemochromatosis), Wilson disease, smoking, and long-term dietary exposure to aflatoxin, a mold toxin found on poorly stored grains and nuts in some parts of the world. According to the CDC overview of liver cancer risk factors, obesity, diabetes, and cirrhosis all sit alongside viral hepatitis on the list.
An important nuance about hepatitis C cure
Curing hepatitis C substantially lowers the risk of liver cancer, but it does not erase it. If cirrhosis or advanced fibrosis was already present when the virus was cleared, the scarred liver remains a fertile ground for tumors, and surveillance continues after the cure. People who are cured before significant scarring develops are in a much better position. This is one of the most common misunderstandings in liver care: a negative virus test is not the same as a normal liver.
Surveillance: who gets checked every six months, and who does not
Liver cancer is one of the few cancers with a genuine early-detection program — but it is not a population screening program like mammography or colonoscopy. It is surveillance of a defined high-risk group. Nobody screens the general public for liver cancer, because in people with a healthy liver the disease is rare enough that testing would cause more harm through false alarms than it would prevent.
Major US liver societies recommend that adults with cirrhosis from any cause, and selected adults with chronic hepatitis B even without cirrhosis, have an abdominal ultrasound every six months, with or without an alpha-fetoprotein blood test. Six months is chosen because it roughly matches how long a hepatocellular carcinoma typically takes to grow from undetectable to a size that is still curable.
| Question | Population screening | Liver cancer surveillance |
|---|---|---|
| Who is invited | Everyone in an age band | Only people with cirrhosis or chronic hepatitis B |
| How often | Every 1 to 10 years depending on the test | Every 6 months, indefinitely |
| Main tool | Varies by cancer | Abdominal ultrasound, with or without an AFP blood test |
| Goal | Find disease in a low-risk crowd | Catch a tumor while transplant, surgery or ablation is still possible |
| Who arranges it | Public health programs and primary care | The hepatology or gastroenterology team following the liver disease |
Surveillance is not free of downsides. Ultrasound picks up benign nodules and cysts that then require extra scans or, occasionally, a biopsy, and a mildly raised AFP can trigger the same chain of tests. Studies of real-world programs show most of this extra testing is mild and short-lived, while the benefit — catching tumors at a curable size — is substantial for people who genuinely belong in the high-risk group.
Blood tests: what AFP can and cannot do
Alpha-fetoprotein, usually shortened to AFP, is a protein that a fetus produces in large amounts and that adults normally produce very little of. Some hepatocellular carcinomas start making it again, which is why it earned a place in liver cancer care.
The two limits you should know
The first limit is sensitivity. A substantial share of small, early hepatocellular carcinomas produce little or no AFP, so a normal result does not rule out a tumor. The second limit is specificity. AFP also rises in active hepatitis, in cirrhosis without cancer, during liver regeneration after injury, and in pregnancy. Because of these two problems, AFP is never used on its own to diagnose or to exclude liver cancer. It is read next to an ultrasound, and its trend over repeated tests often matters more than a single figure.
The rest of the liver panel
A standard liver panel does not detect cancer, but it tells the team how well the liver is coping, which directly shapes what treatment is safe. Clinicians read the liver enzyme ALT as a marker of ongoing liver cell injury, and they read the AST liver enzyme result in the same panel. Bile duct obstruction, which is more typical of cholangiocarcinoma, tends to raise the alkaline phosphatase level. Doctors also check the total bilirubin level, which climbs when the liver cannot clear pigment normally and produces visible jaundice.
Three further results describe the liver’s manufacturing capacity rather than its injury. Liver teams watch the blood albumin level, because a damaged liver makes less of this protein. They review the INR clotting measure, which lengthens when clotting factor production falls. And they follow the platelet count, which often drops in cirrhosis because the enlarged spleen traps platelets. Bilirubin, albumin and INR together feed the Child-Pugh score, one of the numbers that decides whether surgery is an option. If your own results look confusing, it helps to first understand an unexpected liver enzyme spike before assuming the worst.
How liver cancer is diagnosed
Liver cancer is diagnosed differently from almost every other solid tumor, and this surprises many patients.
Imaging that can stand alone
In a person already known to have cirrhosis or chronic hepatitis B, a nodule seen on ultrasound is investigated with a multiphase CT scan or MRI — a scan taken at several timed moments after contrast dye is injected. Hepatocellular carcinoma has a distinctive signature: it lights up brightly as the dye arrives and then washes out faster than the surrounding liver. Radiologists grade this appearance using a standardized system called LI-RADS. When a nodule meets the top category, the imaging alone is considered diagnostic and no biopsy is needed. That is unusual in oncology, where tissue confirmation is normally mandatory, and it exists because the combination of a high-risk liver and a classic imaging pattern is reliable enough on its own.
When a biopsy is still needed
A biopsy is requested when imaging is inconclusive, when the nodule appears in a liver that is not cirrhotic, when cholangiocarcinoma or a metastasis is a realistic alternative, or when a clinical trial requires tissue. Staging then adds a chest CT and sometimes a bone scan, plus an assessment of liver function and general fitness, because the treatment plan depends on all three.
Treatment by stage
Treatment is decided by a multidisciplinary team, and the same tumor size can lead to different recommendations depending on how well the rest of the liver is working.
| Situation | Usual options | Aim |
|---|---|---|
| Single small tumor, liver working well | Surgical removal of the affected segment, or thermal ablation | Cure |
| Small tumor, but poor liver function or cirrhosis complications | Liver transplant assessment; bridging treatment while waiting | Cure of both the tumor and the diseased liver |
| Several tumors confined to the liver | Transarterial chemoembolization or radioembolization | Control and shrink |
| Spread beyond the liver, or invasion of liver blood vessels | Immunotherapy combinations, or targeted oral drugs | Extend life and maintain quality of life |
| Severe liver failure or very poor fitness | Symptom-focused supportive care | Comfort and function |
Transplant criteria
A liver transplant is the only treatment that removes the tumor and the underlying diseased liver in one step. Because donor organs are scarce, eligibility follows agreed limits, most often the Milan criteria: one tumor no larger than five centimeters, or up to three tumors each no larger than three centimeters, with no invasion of blood vessels and no spread outside the liver. People who fall slightly outside these limits are sometimes brought back within them by locoregional treatment first, an approach called downstaging.
Ablation and embolization
Ablation destroys a small tumor in place using heat delivered through a needle guided by imaging; for very small tumors it can match surgery while sparing more healthy liver. Transarterial chemoembolization, shortened to TACE, threads a catheter into the artery feeding the tumor, delivers chemotherapy directly and blocks the vessel. Radioembolization uses tiny radioactive beads through the same route.
Immunotherapy and targeted drugs
For advanced disease, the standard has shifted from single oral targeted drugs to immunotherapy combinations that release the brakes on the immune system so it can attack tumor cells, often paired with a drug that limits the tumor’s blood supply. These regimens are not suitable for everyone — people with certain autoimmune conditions, prior liver transplants, or significant liver failure may need a different route — and side effects need careful monitoring.
Latest scientific advances
Research is moving fastest in two areas: finding tumors earlier with blood tests, and clarifying who still needs surveillance.
The cause of liver cancer in the US is shifting
A 2025 umbrella review — a study that pools the conclusions of many earlier reviews — confirmed that hepatitis B and hepatitis C remain the strongest risk factors, while also flagging fatty liver disease, diabetes, obesity and smoking as significant contributors, and antiviral treatment as a major protective factor. A separate 2024 pooled analysis found that metabolic fatty liver disease is now involved in roughly half of liver cancer cases worldwide, very often alongside another cause rather than instead of it. What this means for you: if you have been told you have fatty liver plus diabetes or excess weight, that combination matters even if you have never had hepatitis or a drinking problem, and it is worth asking your doctor whether your liver has been checked for scarring.
Blood-based tests are being built to help ultrasound
Researchers are testing panels that look for tumor DNA circulating in the blood — fragments shed by cancer cells, sometimes called a liquid biopsy. In a large multicenter study published in 2024, a cell-free DNA score detected early-stage liver cancer roughly twice as often as ultrasound alone in people with cirrhosis, and it worked better still when combined with ultrasound. Another 2025 study used the sugar structures attached to blood proteins, a field known as glycomics, and reported better detection than AFP in people with hepatitis B-related cirrhosis. What this means for you: these tests are promising but still preliminary and not yet part of routine care in the United States, so six-month ultrasound with or without AFP remains the standard, and you should not delay it while waiting for a blood test to replace it.
Surveillance after a hepatitis C cure is still debated
A 2024 review examined what should happen after modern antiviral tablets clear hepatitis C. The consistent finding is that clearing the virus cuts the risk of liver cancer substantially but does not remove it in people who already had advanced fibrosis or cirrhosis, and expert groups still disagree about how long surveillance should continue in those with advanced fibrosis but no cirrhosis. What this means for you: if you were cured of hepatitis C and had significant liver scarring beforehand, do not assume your six-month checks have ended — ask your hepatology team to confirm your plan in writing.
Advanced disease outcomes have improved
Two comprehensive 2024 and 2025 reviews of liver cancer care describe the same shift: immune checkpoint combinations have become the preferred first treatment for advanced hepatocellular carcinoma, with typical survival in trials now measured in years rather than months, and a minority of people achieving long-lasting responses. Both reviews also stress that surveillance remains badly underused, and that many tumors are still found late for reasons that have nothing to do with the science. What this means for you: an advanced diagnosis is no longer the fixed picture it was a decade ago, and treatment decisions are worth discussing with a specialist liver cancer team rather than settling for the first opinion.
Glossary
| Term | Definition |
|---|---|
| Hepatocellular carcinoma (HCC) | The most common primary liver cancer. It grows from hepatocytes, the liver’s main working cells, and usually develops in a liver already damaged by long-term disease. |
| Cholangiocarcinoma | Cancer that starts in the bile ducts rather than the liver cells. It is much less common than hepatocellular carcinoma and is managed differently. |
| Liver metastases | Deposits in the liver from a cancer that began in another organ. They remain that original cancer and are treated as such, not as liver cancer. |
| Alpha-fetoprotein (AFP) | A blood protein that some liver tumors produce. It can be normal in early cancer and raised without cancer, so it is always read alongside imaging. |
| Cirrhosis | Advanced, widespread scarring of the liver caused by years of injury. It is the single strongest setting in which liver cancer develops. |
| MASLD | Metabolic dysfunction-associated steatotic liver disease: fat build-up in the liver linked to excess weight, type 2 diabetes or metabolic syndrome. |
| LI-RADS | A standardized scale radiologists use to grade how likely a liver nodule is to be cancer on CT or MRI, from clearly benign to definitely malignant. |
| Milan criteria | The size and number limits most transplant programs use to decide whether a person with liver cancer can be listed for a donor liver. |
| TACE | Transarterial chemoembolization: chemotherapy delivered straight into the artery feeding a tumor, with that artery then blocked to cut off its blood supply. |
| Ablation | Destroying a small tumor where it sits, usually with heat delivered through a needle positioned using ultrasound or CT guidance. |
Frequently asked questions
What is usually the first sign of liver cancer?
For most people there is no first sign, which is the central difficulty with this disease. When something is noticed, it is often vague upper-right abdominal discomfort, unexplained weight loss, or fatigue — and by then the tumor is usually no longer small. In people who are under six-month surveillance, the tumor is far more often found on a routine ultrasound while they still feel completely well. That is the whole reason surveillance exists for high-risk groups rather than waiting for symptoms to declare themselves.
Can liver cancer be cured?
Yes, in some situations. A single small tumor in a liver that is still working reasonably well can be removed surgically or destroyed by ablation with the intent to cure, and a liver transplant within accepted size limits can cure both the tumor and the underlying liver disease. Cure becomes much less likely once the tumor is large, multiple, invading blood vessels or spreading outside the liver, though modern immunotherapy combinations can still control the disease for a meaningful period.
Does a normal AFP result mean I do not have liver cancer?
No. A meaningful proportion of early liver tumors produce little or no alpha-fetoprotein, so a normal AFP cannot rule cancer out. That is precisely why surveillance is built around ultrasound, with AFP as an optional addition rather than a replacement. The reverse is also true: a mildly raised AFP is common in active hepatitis and in cirrhosis without any tumor. Interpret it alongside your imaging and your other liver results, and discuss the trend with your doctor rather than reacting to one value.
Is liver cancer hereditary?
Liver cancer itself is rarely inherited directly. What can run in families is a condition that damages the liver, such as hemochromatosis (iron overload), Wilson disease, or alpha-1 antitrypsin deficiency, and chronic hepatitis B can pass from mother to child at birth. Genetic variants that raise the risk of fatty liver disease also cluster in families. If several close relatives have had liver disease or liver cancer, mention it to your doctor, because it may change whether you are offered testing for scarring.
If I had hepatitis C and was cured, do I still need checks?
It depends on how much scarring your liver had at the time of the cure. If cirrhosis or advanced fibrosis was present, six-month surveillance normally continues indefinitely, because the risk is reduced but not eliminated. If the virus was cleared before significant scarring developed, ongoing liver cancer surveillance is generally not required. Your hepatology team decides this using elastography or fibrosis blood scores rather than the virus result alone, so ask them to state your plan explicitly.
Do abnormal liver enzymes mean I have liver cancer?
Almost never on their own. Raised liver enzymes are extremely common and usually reflect fatty liver, alcohol, medication effects, a viral infection, or a temporary strain such as intense exercise. Liver enzymes are not a cancer test — plenty of people with liver tumors have normal enzymes, and plenty of people with high enzymes have no tumor. Their real value is showing your doctor that the liver deserves a closer look, which may then include imaging and an assessment of scarring.
Sources
- MedlinePlus, National Library of Medicine — Liver Cancer — NIH, 2026 — MedlinePlus liver cancer overview
- Centers for Disease Control and Prevention — About Liver Cancer — CDC, 2026 — CDC liver cancer page
- Mayo Clinic — Liver cancer: symptoms and causes — Mayo Clinic, 2026 — Mayo Clinic liver cancer article
- Hwang SY, Danpanichkul P, Agopian V, et al. — Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment — Clinical and Molecular Hepatology, 2024 — DOI 10.3350/cmh.2024.0824
- Mauro E, de Castro T, Zeitlhoefler M, et al. — Hepatocellular carcinoma: epidemiology, diagnosis and treatment — JHEP Reports, 2025 — DOI 10.1016/j.jhepr.2025.101571
- Wang J, Qiu K, Zhou S, et al. — Risk factors for hepatocellular carcinoma: an umbrella review of systematic reviews and meta-analyses — Annals of Medicine, 2025 — DOI 10.1080/07853890.2025.2455539
- Crane H, Eslick GD, Gofton C, et al. — Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis — Clinical and Molecular Hepatology, 2024 — DOI 10.3350/cmh.2024.0109
- Chen L, Wu T, Fan R, et al. — Cell-free DNA testing for early hepatocellular carcinoma surveillance — EBioMedicine, 2024 — DOI 10.1016/j.ebiom.2023.104962
- Su R, Tao X, Yan L, et al. — Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: a cohort study — Hepatology, 2025 — DOI 10.1097/HEP.0000000000001316
- Pan CQ, Park AJ, Park JS — New perspectives in hepatocellular carcinoma surveillance after hepatitis C virus eradication — Gastroenterology Report, 2024 — DOI 10.1093/gastro/goae085
- Hui S, Nguyen A, Le S, et al. — Clinical outcomes of hepatocellular carcinoma surveillance — Internal Medicine Journal, 2024 — DOI 10.1111/imj.16405
- Jeng WJ, Yip TC, Lok AS — Hepatitis B: a review — JAMA, 2026 — DOI 10.1001/jama.2026.6070
Further reading
- Cirrhosis: symptoms, causes and treatments
- Hepatitis B: symptoms, causes and treatments
- Hepatitis C: symptoms, testing and how the cure works
- High liver enzymes: how to read ALT, AST, ALP and GGT
- Coagulation tests: understanding your results
Understand your lab results with BloodSense
Liver reports are dense, and the numbers that matter most for liver health are rarely the ones that stand out on the page. BloodSense reads your uploaded results and explains them in plain language — what a raised liver enzyme, a low albumin, a long clotting time or an out-of-range alpha-fetoprotein actually indicates, and which values are worth raising with your doctor. It helps you understand your own results and prepare better questions; it does not diagnose liver cancer and it does not replace your medical team.
